Last reviewed · How we verify
Hu1124 (EFALIZUMAB)
Hu1124, also known as Efalizumab, is a CD11a-directed Humanized IgG1 Antibody developed by Genentech. It targets the leukocyte adhesion glycoprotein LFA-1 alpha, which plays a key role in the immune response. Efalizumab is approved for the treatment of plaque psoriasis and was first approved by the FDA in 2003. The commercial status of Efalizumab is patented, as it is still owned by Genentech. Key safety considerations include the risk of serious infections and the potential for reactivation of latent infections.
At a glance
| Generic name | EFALIZUMAB |
|---|---|
| Sponsor | Roche |
| Drug class | CD11a-directed Humanized IgG1 Antibody |
| Target | Leukocyte adhesion glycoprotein LFA-1 alpha |
| Modality | Monoclonal antibody |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
| First approval | 2003 |
Approved indications
- Plaque psoriasis
Common side effects
Key clinical trials
- PsoBest - The German Psoriasis Registry
- Spanish Registry of Systemic Treatments in Psoriasis
- Study of the Drug Efalizumab (Raptiva), for Adult Patients With Moderate to Severe Plaque Psoriasis (PHASE3)
- Prevention of Autoimmune Destruction and Rejection of Human Pancreatic Islets Following Transplantation for Insulin Dependent Diabetes Mellitus (PHASE1,PHASE2)
- Discoid Lupus Erythematosus of the Scalp and a Trial of Biologic Therapy With Raptiva (PHASE2)
- Efalizumab for Moderate to Severe Atopic Dermatitis (PHASE1)
- Evaluate Whether Combination Therapy With Methotrexate and Raptiva in Psoriasis Patients is Safe and Increases Efficacy (PHASE1,PHASE2)
- A Multicentre, Open Label Phase IIIb/IV Study of Subcutaneously Administered Raptiva in the Treatment of Adult Subjects With Moderate to Severe Plaque Psoriasis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Hu1124 CI brief — competitive landscape report
- Hu1124 updates RSS · CI watch RSS
- Roche portfolio CI